APL Clinical Trials

2 recruiting

APL Trials at a Glance

184 actively recruiting trials for apl are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 2 with 54 trials, with the heaviest enrollment activity in New York, Houston, and Boston. Lead sponsors running apl studies include Institute of Hematology & Blood Diseases Hospital, China, National Heart, Lung, and Blood Institute (NHLBI), and Neuralink Corp.

Treatments under study

About APL Clinical Trials

Looking for clinical trials for APL? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new APL trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about APL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 184 trials

Recruiting

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

Muscular DystrophiesMuscle MyopathiesHereditary Spastic Paraplegias+2 more
National Institute of Neurological Disorders and Stroke (NINDS)9,300 enrolled1 locationNCT01568658
Recruiting
Phase 1

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.40 enrolled15 locationsNCT07140016
Recruiting
Phase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Severe Aplastic Anemia (SAA)Hypo-Plastic Myelodysplastic Syndrome (MDS)
National Heart, Lung, and Blood Institute (NHLBI)56 enrolled1 locationNCT03520647
Recruiting
Not Applicable

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas

Diffuse Astrocytoma, IDH-MutantOligodendrogliomaOligodendroglioma, Anaplastic
Oslo University Hospital225 enrolled1 locationNCT05190172
Recruiting
Phase 2

Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

Aplastic Anemia
Assistance Publique - Hôpitaux de Paris52 enrolled26 locationsNCT06646497
Recruiting
Phase 2

Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor

Sickle Cell DiseaseStem Cell Transplant ComplicationsPure Red Cell Aplasia+1 more
University of Calgary12 enrolled1 locationNCT03214354
Recruiting

Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis

Gastric CarcinomaIntestinal MetaplasiaGastritis Chronic+1 more
Yongquan Shi450 enrolled1 locationNCT07542652
Recruiting
Phase 1Phase 2

JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure

Severe Aplastic AnemiaSingle Lineage Cytopenias, T-LGLHypoplastic MDS
National Heart, Lung, and Blood Institute (NHLBI)145 enrolled1 locationNCT05998408
Recruiting

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Severe Aplastic AnemiaTelomere Biology DisordersInherited Bone Marrow Failure Syndromes
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT05012111
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Not Applicable

Neuromodulation to Enhance Motor Function in HSP

Hereditary Spastic Paraplegia
Rahul Sachdeva15 enrolled1 locationNCT07417943
Recruiting
Phase 3

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

Hereditary Spastic Paraplegia Type 50
Elpida Therapeutics SPC24 enrolled2 locationsNCT06692712
Recruiting
Phase 2

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

Severe Aplastic Anemia
Northside Hospital, Inc.20 enrolled2 locationsNCT02828592
Recruiting

Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)

Aplasia Cutis Congenita
UConn Health600 enrolled1 locationNCT01630421
Recruiting
Phase 3

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia (APL)
Quetzal Therapeutics150 enrolled4 locationsNCT07504458
Recruiting
Phase 1

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

GlioblastomaAnaplastic AstrocytomaAnaplastic Oligodendroglioma+2 more
University of Nebraska24 enrolled1 locationNCT05698524
Recruiting
Phase 2

Romiplostim Versus rhTPO for Platelet Engraftment After Transplant in MDS and AA

MDS (Myelodysplastic Syndrome)Aplastic Anemia (AA)
The First Affiliated Hospital of Soochow University66 enrolled1 locationNCT07400341
Recruiting
Phase 2

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Myelodysplastic SyndromeAplastic Anemiade Novo Myelodysplastic Syndrome+1 more
M.D. Anderson Cancer Center140 enrolled1 locationNCT01624805
Recruiting
Not Applicable

Self-balancing Personal Exoskeleton for SCI (WIP)

Spinal Cord InjuriesParaplegia and Tetraplegia
Wandercraft10 enrolled1 locationNCT07536386
Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931